Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

TSPAN1, a Novel Protein Involved in Head and Neck Squamous Cell Carcinoma Chemoresistance

  • Garcia Mayea, Yoelsis|||0000-0002-9395-7471
  • Mir Pérez, Cristina|||0000-0003-3137-6521
  • Carballo, Laia
  • Castellvi, Josep|||0000-0001-5745-9996
  • Temprana-Salvador, Jordi|||0000-0001-9516-1680
  • Lorente Guerrero, Juan|||0000-0002-3264-0251
  • Benavente, Sergi|||0000-0002-2700-3522
  • García-Pedrero, Juana María|||0000-0002-5891-9488
  • Allonca, Eva|||0000-0002-2532-5421
  • Rodrigo, Juan Pablo|||0000-0003-3063-0890
  • Lleonart, Matilde Esther|||0000-0002-6196-7405
Sensitization of resistant cells and cancer stem cells (CSCs) represents a major challenge in cancer therapy. A proteomic study revealed tetraspanin-1 (TSPAN1) as a protein involved in acquisition of cisplatin (CDDP) resistance (Data are available via ProteomeXchange with identifier PXD020159). TSPAN1 was found to increase in CDDP-resistant cells, CSCs and biopsies from head and neck squamous cell carcinoma (HNSCC) patients. TSPAN1 depletion in parental and CDDP-resistant HNSCC cells reduced cell proliferation, induced apoptosis, decreased autophagy, sensitized to chemotherapeutic agents and inhibited several signaling cascades, with phospho-SRC inhibition being a major common target. Moreover, TSPAN1 depletion in vivo decreased the size and proliferation of parental and CDDP-resistant tumors and reduced metastatic spreading. Notably, CDDP-resistant tumors showed epithelial-mesenchymal transition (EMT) features that disappeared upon TSPAN1 inhibition, suggesting a link of TSPAN1 with EMT and metastasis. Immunohistochemical analysis of HNSCC specimens further revealed that TSPAN1 expression was correlated with phospho-SRC (pSRC), and inversely with E-cadherin, thus reinforcing TSPAN1 association with EMT. Overall, TSPAN1 emerges as a novel oncogenic protein and a promising target for HNSCC therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Therapy-Induced Modulation of the Tumor Microenvironment, New Opportunities for Cancer Therapies

  • Benavente, Sergi|||0000-0002-2700-3522
  • Sánchez García, Almudena
  • Naches Solsona, Silvia
  • Lleonart, Matilde Esther|||0000-0002-6196-7405
  • Lorente Guerrero, Juan|||0000-0002-3264-0251
Advances in immunotherapy have achieved remarkable clinical outcomes in tumors with low curability, but their effects are limited, and increasing evidence has implicated tumoral and non-tumoral components of the tumor microenvironment as critical mediators of cancer progression. At the same time, the clinical successes achieved with minimally invasive and optically-guided surgery and image-guided and ablative radiation strategies have been successfully implemented in clinical care. More effective, localized and safer treatments have fueled strong research interest in radioimmunotherapy, which has shown the potential immunomodulatory effects of ionizing radiation. However, increasingly more observations suggest that immunosuppressive changes, metabolic remodeling, and angiogenic responses in the local tumor microenvironment play a central role in tumor recurrence. In this review, we address challenges to identify responders vs. non-responders to the immune checkpoint blockade, discuss recent developments in combinations of immunotherapy and radiotherapy for clinical evaluation, and consider the clinical impact of immunosuppressive changes in the tumor microenvironment in the context of surgery and radiation. Since the therapy-induced modulation of the tumor microenvironment presents a multiplicity of forms, we propose that overcoming microenvironment related resistance can become clinically relevant and represents a novel strategy to optimize treatment immunogenicity and improve patient outcome.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeting Sphingolipids for Cancer Therapy

  • Companioni, Osmel
  • Mir Pérez, Cristina|||0000-0003-3137-6521
  • Garcia Mayea, Yoelsis|||0000-0002-9395-7471
  • Lleonart, Matilde Esther|||0000-0002-6196-7405
Sphingolipids are an extensive class of lipids with different functions in the cell, ranging from proliferation to cell death. Sphingolipids are modified in multiple cancers and are responsible for tumor proliferation, progression, and metastasis. Several inhibitors or activators of sphingolipid signaling, such as fenretinide, safingol, ABC294640, ceramide nanoliposomes (CNLs), SKI-II, α-galactosylceramide, fingolimod, and sonepcizumab, have been described. The objective of this review was to analyze the results from preclinical and clinical trials of these drugs for the treatment of cancer. Sphingolipid-targeting drugs have been tested alone or in combination with chemotherapy, exhibiting antitumor activity alone and in synergism with chemotherapy in vitro and in vivo. As a consequence of treatments, the most frequent mechanism of cell death is apoptosis, followed by autophagy. Aslthough all these drugs have produced good results in preclinical studies of multiple cancers, the outcomes of clinical trials have not been similar. The most effective drugs are fenretinide and α-galactosylceramide (α-GalCer). In contrast, minor adverse effects restricted to a few subjects and hepatic toxicity have been observed in clinical trials of ABC294640 and safingol, respectively. In the case of CNLs, SKI-II, fingolimod and sonepcizumab there are some limitations and absence of enough clinical studies to demonstrate a benefit. The effectiveness or lack of a major therapeutic effect of sphingolipid modulation by some drugs as a cancer therapy and other aspects related to their mechanism of action are discussed in this review.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

SDCBP modulates stemness and chemoresistance in head and neck squamous cell carcinoma through src activation

  • Mir Pérez, Cristina|||0000-0003-3137-6521
  • Garcia Mayea, Yoelsis|||0000-0002-9395-7471
  • García Fernández, Laia|||0009-0008-3105-493X
  • Herrero, Pol|||0000-0002-8746-7214
  • Canela, Núria|||0000-0003-0261-2396
  • Tabernero, Rocío|||0000-0002-5949-0898
  • Lorente Guerrero, Juan|||0000-0002-3264-0251
  • Castellvi, Josep|||0000-0001-5745-9996
  • Allonca, Eva|||0000-0002-2532-5421
  • García-Pedrero, Juana
  • Rodrigo, Juan Pablo|||0000-0003-3063-0890
  • Carracedo, Ángel|||0000-0003-1085-8986
  • Lleonart, Matilde Esther|||0000-0002-6196-7405
To characterize the mechanisms that govern chemoresistance, we performed a comparative proteomic study analyzing head and neck squamous cell carcinoma (HNSCC) cells: CCL-138 (parental), CCL-138-R (cisplatin-resistant), and cancer stem cells (CSCs). Syntenin-1 (SDCBP) was upregulated in CCL-138-R cells and CSCs over parental cells. SDCBP depletion sensitized biopsy-derived and established HNSCC cell lines to cisplatin (CDDP) and reduced CSC markers, Src activation being the main SDCBP downstream target. In mice, SDCBP-depleted cells formed tumors with decreased mitosis, Ki-67 positivity, and metastasis over controls. Moreover, the fusocellular pattern of CCL-138-R cell-derived tumors reverted to a more epithelial morphology upon SDCBP silencing. Importantly, SDCBP expression was associated with Src activation, poor differentiated tumor grade, advanced tumor stage, and shorter survival rates in a series of 382 HNSCC patients. Our results reveal that SDCBP might be a promising therapeutic target for effectively eliminating CSCs and CDDP resistance.